Feature Analyst Alert and 4 Brief Updates
11 November 2015 - 12:00AM
InvestorsHub NewsWire
NEW YORK, NY – November 10, 2015 -- InvestorsHub NewsWire
-- Small Cap Street makes the connection between sophisticated
investors and high quality micro and small cap companies that are
currently undervalued. We are an issuer of reports written by
experienced financial analysts and who provide a straight forward
assessment of a profiled company. They include stocks traded in the
NYSE, NASDAQ, and OTCBB exchanges.
*Feature Analyst Alert*
This week's NASDAQ alert is the lowest priced with the most upside
potential that we have covered in a long time. Another reason we
like this one so much their technology is proprietary.
(NASDAQ: AMDA) is in the hot biotech /
biomaterial space currently holding 56 patents issued and another
37 patents pending. As if that's not enough to get you excited,
(NASDAQ: AMDA) has earnings due this week Thursday November 12th,
2015.
Earnings PR- http://finance.yahoo.com/news/amedica-corporation-release-third-quarter-201500678.html
Link to Amedica's Investor presentation at their website- http://investors.amedica.com/downloads.cfm
Link to Amedica's website providing information on the two analyst'
that cover their securities Needham and JMP Securities - http://investors.amedica.com/analysts.cfm
Needham and JMP's targets are $1 and $3/share.
If you would like to receive profiles in real time, text "Street"
to 25827
4 Brief Investor Updates
Peregrine Pharmaceuticals, Inc. (NASDAQ:
PPHM) is a biopharmaceutical company with a pipeline of novel
drug candidates in clinical trials focused on the treatment of
cancer. The company's lead immunotherapy candidate, bavituximab, is
in Phase III development for the treatment of second-line non-small
lung cancer (the "SUNRISE trial") along with several
investigator-sponsored trials evaluating other treatment
combinations and additional oncology indications.
The company just announced results from multiple new preclinical
studies demonstrating enhanced anti-tumor activity and immune
activation for combinations of a preclinical bavituximab (the PPHM
lead immunotherapy candidate) equivalent and checkpoint inhibitors
such as anti-PD-1 and anti-CTLA-4 in preclinical models of breast
cancer and melanoma. Results from these studies were presented at
the 2015 annual meeting of the Society for Immunotherapy of Cancer
on November 4 - 8, 2015.
Amarin Corp. Plc (NASDAQ:
AMRN) is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve
cardiovascular health. Amarin's product development program
leverages its extensive experience in lipid science and the
potential therapeutic benefits of polyunsaturated fatty acids.
Amarin's clinical program includes commitment to an ongoing
outcomes study. Amarin's first product, Vascepa® (icosapent ethyl)
capsules, is a highly pure EPA omega-3 prescription product.
Key Amarin achievements since June 30, 2015 include: REDUCE-IT,
study is progressing on schedule with enrollment now over 97%
complete; Recognized $21.3 million in net product revenue from
Vascepa® (icosapent ethyl) sales in Q3 2015 compared to $14.1
million in Q3 2014, an increase of 51%; Increased normalized
prescriptions, based on data from Symphony Health Solutions, by 51%
in Q3 2015 compared to Q3 2014.
RCS CAPITAL Corp. (NYSE:
RCAP) is a full-service investment firm focused on the
individual retail investor. RCS Capital's business is designed to
capitalize, support, grow and maximize value for the investment
programs it distributes and the independent advisors and clients it
serves.
On November 9, 2015 the company announced the following changes:
Completes $27 Million Issuance of New Senior Unsecured Promissory
Notes to Provide Incremental Liquidity; $12 Million Issued to
Affiliates of AR Capital, $15 Million Issued to Affiliates of Luxor
Capital Group; Company and its Lenders Agree to Certain
Modifications to Credit Facilities; Company Agrees to Sell Hatteras
Liquid Alternatives Platform to the Hatteras Funds Management
Group; Company Announces Changes to Board of Directors; Independent
Board Members of RCS Capital Given Proxy to Vote Majority Class B
Share and Series D-1 Preferred Shares; Company Given Right to
Purchase B Share for $1.
Northwest Biotherapeutics, Inc. (NASDAQ:
NWBO) is a biotechnology company developing immunotherapy
products to treat cancers, without toxicities of the kind
associated with chemotherapies. The Company has a broad
platform technology for DCVax dendritic cell-based vaccines.
The Company's lead program is a 348-patient Phase III trial in
newly diagnosed Glioblastoma multiforme (GBM), which is on a
partial clinical hold in regard to new screening of patients.
Last month the company raised $30 million with Woodford Investment
Management in the UK. Woodford will purchase $30 million of the
Company's common stock at $5.50 per share, for a total of 5,454,545
shares, raising Woodford's total holdings to 25,915,937 shares, or
about 28.1% of the Company. The purchase will take place in a
closing on or before October 22, 2015.
With the new funding from Woodford the company will move its
clinical programs for DCVax-L and DCVax-Direct ahead.
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and
information, as defined within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, and is subject to the Safe Harbor created by those
sections. This material contains statements about expected future
events and/or financial results that are forward-looking in nature
and subject to risks and uncertainties. Such forward- looking
statements by definition involve risks, uncertainties and other
factors, which may cause the actual results, performance or
achievements of mentioned company to be materially different from
the statements made herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis
by a 3rd party research analyst. However, we are only human and may
make mistakes. This report was prepared for informational purposes
only. A full disclaimer can be found by viewing the full
analyst report. We do not engage in high frequency trading or hold
any positions of profiled company.
For more information and services provided beyond this release
please use contact information provided below. If you notice any
errors or omissions, please notify us below.
Source: Small Cap Street
Contact: editor@smallcapstreet.com
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Apr 2024 to May 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From May 2023 to May 2024